内镜下全腹膜外Sublay修补在腹壁疝中的应用

目的评价腹壁疝内镜下全腹膜外Sublay(TES)手术的效果并总结经验。方法回顾性总结国内10所医院自2016年3月至2019年7月115例腹壁疝内镜下TES手术的患者资料。分析患者情况、疝的特点、手术经过和结果。结果115例计划实施TES的患者中,因严重腹膜破损中转为IPOM修补患者1例,其余均成功手术。可以缝合缺损患者108例(94.74%),需要永久补片固定患者15例(13.16%)。放置引流患者76例(66.67%),中位手术时间为144 min,术中无严重并发症发生。随访时间3~45个月,总并发症发生率为20例(17.54%),其中出现血清肿患者5例(4.38%)。绝大多数患者术后仅出现轻微疼痛,未出现慢性疼痛。结论在腹壁疝的治疗中,对熟悉腹壁解剖的外科医师而言,TES是一种有效、安全的修复手段。在熟悉手术的基础上适应症可逐步拓展。     

药品包装材料对液体药剂质量的影响

目的:探讨药品包装材料与用药安全的关系。方法:参考有关文献并结合我国实际情况进行分析。结果:药品包装材料质量对人体能产生一定的危害,对药品质量也产生一定的影响。结论:应按药品的理化性质选用合适的药品包装材料,药品包装材料生产企业也要按专业标准化生产药品包装材料,以适应各种药品包装的需求。     

人β防御素-2基因在SPC细胞中的转染表达

目的合成人β防御素-2(hum anβ-defensin-2,hBD-2)基因并构建其真核表达载体,转染SPC细胞,检测其表达,明确hBD-2重组载体的表达活性,为hBD-2基因转染和表达的研究奠定基础。方法根据Genebank中的hBD-2结构基因序列设计合成三条引物,用PCR延伸扩增的方法合成hBD-2基因,克隆入真核表达载体pLXSN;通过脂质体转染法将pLXSN-hBD-2导入SPC细胞,采用W estern-b lot法检测hBD-2的表达。结果经凝胶电泳及测序分析,证实合成的基因与原序列一致,并成功克隆到真核表达载体pLXSN上,所构建的真核表达重组载体pLX-SN-hBD-2转染SPC细胞后呈现有效表达。结论成功构建了PCR合成的hBD-2基因真核表达重组载体pLXSN-hBD-2,通过基因转染的方法导入SPC细胞并获得表达hBD-2,为进一步的动物转基因抗感染实验研究提供了依据。     

CD44分子对胃癌细胞腹膜种植影响的体外实验研究

目的体外研究CD44分子对胃癌细胞(MKN45)腹膜种植转移的影响.方法在体外预先将抗CD44S抗体与MKN45细胞在细胞培养箱中作用45 min,然后在24孔培养板或Boyden小室中与生长良好的间皮细胞共同培养不同时间,在显微镜下直接计数与间皮细胞粘附的MKN45细胞,而用MTT法评估胃癌细胞在间皮细胞间的迁移和侵袭情况.结果在体外,抗CD44S抗体对MKN45细胞与间皮细胞间的粘附有明显的抑制作用(P＜0.01),在高浓度时对迁移和侵袭也有一定的抑制作用.结论CD44分子参与了胃癌细胞腹膜种植转移过程,抗CD44S抗体对胃癌细胞腹膜种植转移有一定的抑制作用.     

化工工艺设计过程中几种决策方法的应用

催化裂化汽油通过加氢处理可有效降低硫含量,是清洁汽油或清洁汽油调和油生产的重要过程。随着环保标准的日益严格,汽油加氢技术的研发和使用正日益受到重视,在技术开发、工艺设计、项目投资的过程中要面临诸多决策问题,从管理学角度对不同级别决策问题适用的决策方法和模型进行了介绍,并对定量决策方法、定性决策方法以及定量与定性相结合的决策方法使用场合提出了一些建议。     

Changes in oxidative nucleic acid modifications and inflammation following one-week treatment with the bile acid sequestrant sevelamer: Two randomised,placebo-controlled trials

AimsSevelamer has been reported to have anti-oxidative and anti-inflammatory effects as well as effects on glycaemic control and plasma lipids. The aim of this study was to determine the effects of one-week treatment with sevelamer on oxidative nucleic acid modifications and inflammation markers.MethodsTwo double-blinded studies including 30 patients with type 2 diabetes (T2D) and 20 healthy individuals were conducted. Participants were randomised to one week of treatment with sevelamer (1600 mg three times daily) or placebo. RNA and DNA oxidation, measured by urinary excretion of 8-oxo-7,8-dihydroguanosine(8-oxoGuo) and (8-oxo-7,8-dihydro-2′-deoxyguanosine(8-oxodG), and markers of inflammation were determined before and after the intervention.ResultsIn patients with T2D there was no significant placebo-corrected reduction in 8-oxoGuo or 8-oxodG. However, a reduction in 8-oxoGuo was observed within the group treated with sevelamer (∆8-oxoGuo/creatinine (median[IQR]): −0.04 [−0.24; 0.01] nmol/mmol, p = 0.02). A sevelamer-mediated reduction in interleukin-2 (p = 0.04) and a trend towards reduction in interleukin-6 (p = 0.053) were found in patients with T2D.ConclusionsThis study reveals a potential effect of sevelamer treatment on inflammation and possible oxidative RNA modifications. The potential protective effects of sevelamer in terms of cardiovascular disease in patients with T2D need further investigation.     

Silencing of miRNA-218 promotes migration and invasion of breast cancer via Slit2-Robo1 pathway

MiRNAs play an important role in regulating tumor migration and invasion, and abnormal expression of miRNAs occurs in various kinds of human cancers. In this essay, it is reported that the level of miRNA-218 decreases in metastatic breast cancer cells, moreover, miRNA-218 suppresses breast cancer cells migration and invasion through binding Robo1 (one of Slit receptors) to its 3′UTR. MiRNA-218 restoration suppresses Robo1 expression and inhibits breast cancer cells invasion and migration. What the results describe is that the function of Robo1 regulated by miRNA-218 may provide a new strategy for inhibiting migration and invasion of breast cancer cells.     

解脲脲原体和微小脲原体生长特性及分离

目的探讨解脲脲原体(ureaplasma urealyticum,UU)和微小脲原体(ureaplasma parvum,UP)的生长特性及其分离。方法从妇科门诊随机取266例阴道分泌物标本,通过固、液体培养后应用PCR,基因测序鉴别UU和UP,并筛选出与标准株(ATCC700970)序列相同的UP。取UU标准株T960(CX8=ATCC27618),分别进行培养,绘出生长曲线。结果标本中感染脲原体的有118例,其中UP阳性92例,UU阳性16例,混合阳性10例。固体培养可见大、中、小型的棕色菌落。UU生长周期为22h,UP为30h。液体培养基pH值达到7.5,UU需要13h,UP需要20h。结论临床分离发现UP阳性数高于UU,液体培养中UP的生长周期长于UU,pH值变化速度UP慢于UU,进一步证实了UP和UU是两个不同的种。     

Efficacy and safety of tumor necrosis factor-α blockers for ulcerative colitis: A systematic review and meta-analysis of published randomized controlled trials

To evaluate the efficacy and safety of TNF-α blockers for ulcerative colitis. A systematic search for randomized controlled trials (RCTs) of TNF-α blockers for treatment of ulcerative colitis (UC) were performed in PubMed, Web of Science, Embase and cochrane clinical trial. We estimated Pooled estimates of the odds ratio (OR) and relevant 95% confidence interval (CI) using fixed effects model or random effects model as appropriate. Heterogeneity, publication bias, and subgroup analyses were conducted. Nine randomized controlled studies met the selection criteria with a total of 2518 patients. Five studies compared Infliximab with placebo. Two studies compared Infliximab to corticosteroids. Two studies compared Adalimumab to placebo. One study compared subcutaneous golimumab to placebo. Short-term response, short-term remission, long-term remission and mucosal healing were better in the TNF-α blocker group than in the control group (p < 0.05). TNF-α blockers decreased the colectomy rate and serious adverse reactions (p < 0.05). The TNF-α blockers were superior to controls in achieving short-term clinical response/remission, long-term remission and mucosal healing and decreased the colectomy rate and serious adverse reactions.